Acute Myeloid Leukemia (AML)

Mark J. Levis, M.D., Ph.D., professor of oncology, medicine and pharmacology in the Division of Hematologic Malignancies at the Johns Hopkins University School of Medicine, co-directs the Hematologic Malignancies and Bone Marrow Transplantation Program and directs the Adult Leukemia Service at the Johns Hopkins Sidney Kimmel Cancer Center. In addition to his role within the Kimmel Cancer Center, he serves on the faculty for the Johns Hopkins Graduate Training Program in Cellular and Molecular Medicine, a Ph.D. program that prepares scientists to conduct laboratory research at the cellular and

Dr. Josh Sasine is a hematologist and oncologist at UCLA specializing in the treatment of hematologic malignancies, including hematopoietic stem cell transplantation (bone marrow transplantation), cellular therapy, and clinical trials of novel therapeutics. He is the Director of the Chimeric Antigen Receptor T-Cell (CAR T) Program. He treats patients with blood and bone marrow disorders such as leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, amyloidosis, aplastic anemia, Waldenstrom Macroglobulinemia, polycythemia vera, primary myelofibrosis, paroxysmal nocturnal hemoglobinuria

Dr. David Sallman is an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center. Dr. Sallman’s clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Dr. Sallman earned his MD degree from the University of South Florida College of Medicine. He completed an Internal Medicine Residency at Massachusetts General Hospital and, most recently, a Hematology/Oncology Fellowship at Moffitt Cancer Center. His research interests focus on the development of novel, targeted therapeutic strategies (Phase I and

Dr. Rampal is a hematology-oncology physician who specializes in the treatment of myeloproliferative neoplasms (MPN) and leukemia. He is dedicated to providing my patients with the best possible care, taking into account the individual needs of each patient and his or her family. In addition, Dr. Rampal is an active researcher whose focus is the development of new and innovative approaches to treating MPNs and leukemia. He is working to understand the genetic events that contribute to the development and progression of leukemia and MPNs in the hope of developing new targeted therapies for